Lyell Immunopharma (LYEL) Competitors $12.82 -0.48 (-3.61%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$12.84 +0.03 (+0.20%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYEL vs. AMLX, PHAT, AKBA, AVXL, IMNM, IOVA, AVBP, TSHA, NAGE, and DNTHShould you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Amylyx Pharmaceuticals (AMLX), Phathom Pharmaceuticals (PHAT), Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), Immunome (IMNM), Iovance Biotherapeutics (IOVA), ArriVent BioPharma (AVBP), Taysha Gene Therapies (TSHA), Niagen Bioscience (NAGE), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Lyell Immunopharma vs. Its Competitors Amylyx Pharmaceuticals Phathom Pharmaceuticals Akebia Therapeutics Anavex Life Sciences Immunome Iovance Biotherapeutics ArriVent BioPharma Taysha Gene Therapies Niagen Bioscience Dianthus Therapeutics Amylyx Pharmaceuticals (NASDAQ:AMLX) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends. Do institutionals & insiders have more ownership in AMLX or LYEL? 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 22.3% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer AMLX or LYEL? In the previous week, Amylyx Pharmaceuticals had 8 more articles in the media than Lyell Immunopharma. MarketBeat recorded 12 mentions for Amylyx Pharmaceuticals and 4 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.23 beat Amylyx Pharmaceuticals' score of 1.13 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyell Immunopharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, AMLX or LYEL? Amylyx Pharmaceuticals has a beta of -0.44, meaning that its share price is 144% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Which has higher valuation & earnings, AMLX or LYEL? Amylyx Pharmaceuticals has higher revenue and earnings than Lyell Immunopharma. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals$87.37M11.89-$301.74M-$2.50-4.66Lyell Immunopharma$60K4,104.54-$342.99M-$24.29-0.53 Is AMLX or LYEL more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -552,328.31%. Amylyx Pharmaceuticals' return on equity of -82.48% beat Lyell Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -82.48% -70.15% Lyell Immunopharma -552,328.31%-85.58%-68.85% Do analysts rate AMLX or LYEL? Amylyx Pharmaceuticals presently has a consensus target price of $12.25, suggesting a potential upside of 5.15%. Lyell Immunopharma has a consensus target price of $15.00, suggesting a potential upside of 17.00%. Given Lyell Immunopharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 SummaryAmylyx Pharmaceuticals beats Lyell Immunopharma on 10 of the 17 factors compared between the two stocks. Get Lyell Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYEL vs. The Competition Export to ExcelMetricLyell ImmunopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$255.51M$2.59B$5.87B$10.14BDividend YieldN/A56.51%5.68%4.59%P/E Ratio-0.5323.5374.5225.93Price / Sales4,104.54699.42549.78198.13Price / CashN/A171.1637.5660.44Price / Book0.495.3712.166.29Net Income-$342.99M$32.95M$3.28B$270.77M7 Day Performance5.51%1.28%0.87%3.88%1 Month Performance18.37%6.09%4.96%4.88%1 Year Performance-47.89%-2.15%60.74%26.01% Lyell Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYELLyell Immunopharma2.8028 of 5 stars$12.82-3.6%$15.00+17.0%-44.3%$255.51M$60K-0.53270Positive NewsAMLXAmylyx Pharmaceuticals1.9504 of 5 stars$9.61+2.4%$12.25+27.5%+367.9%$856.03M$87.37M-3.84200Positive NewsPHATPhathom Pharmaceuticals2.5199 of 5 stars$11.94-2.0%$17.50+46.6%-39.3%$846.10M$55.25M-2.52110Positive NewsAKBAAkebia Therapeutics3.8047 of 5 stars$3.11-1.1%$6.75+117.4%+104.9%$823.26M$160.18M-18.26430Positive NewsAnalyst DowngradeAVXLAnavex Life Sciences3.6534 of 5 stars$9.47-1.8%$44.00+364.6%+79.8%$812.09MN/A-16.5940News CoveragePositive NewsAnalyst ForecastIMNMImmunome2.1052 of 5 stars$9.27-2.5%$22.50+142.7%-37.4%$806.43M$9.04M-3.0140IOVAIovance Biotherapeutics4.3371 of 5 stars$2.21-1.1%$11.90+439.7%-76.0%$797.88M$164.07M-1.79500AVBPArriVent BioPharma1.9481 of 5 stars$19.60+2.5%$39.14+99.7%-17.2%$794.75MN/A-4.8740Positive NewsTSHATaysha Gene Therapies2.1254 of 5 stars$2.89-1.2%$8.29+187.2%+40.2%$786.76M$8.33M-8.48180Insider TradeNAGENiagen Bioscience2.0209 of 5 stars$9.70-2.0%$13.42+38.4%N/A$773.58M$99.60M46.19120Analyst DowngradeDNTHDianthus Therapeutics2.8783 of 5 stars$23.99+1.8%$54.00+125.1%+33.6%$770.47M$6.24M-7.3680Trending NewsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies AMLX Alternatives PHAT Alternatives AKBA Alternatives AVXL Alternatives IMNM Alternatives IOVA Alternatives AVBP Alternatives TSHA Alternatives NAGE Alternatives DNTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LYEL) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LYEL Stock Alerts